Saturday 17 October 2026
Export TNGX’s income statement to Excel — free account
Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
22.04
0.66
−2.91%
Follow TNGX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 3 | 1 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
9.88 | (1.01) | 2.52 | 1.27 | 2.95 | 0.69 | — | — |
P/S ratio |
16.50 | 8.02 | 25.84 | 25.82 | 18.34 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
5.58 | (1.74) | 1.76 | 2.48 | 6.42 | 1.76 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
(34.63) | (9.21) | (34.36) | (22.71) | (40.20) | (1,027.12) | — | — |
Beneish M-Score |
— | — | — | 4.66 | 0.18 | — | — | — |
P/B ratio |
2.97 | 1.69 | 3.73 | 2.57 | 1.97 | 1.51 | — | — |
Price to Tangible BV |
2.97 | 1.69 | 3.73 | 2.57 | 1.97 | 1.51 | — | — |
EV/Sales |
10.99 | 1.89 | 16.59 | 11.07 | 5.23 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(4.94) | (0.61) | (5.14) | (2.52) | (3.25) | 0.00 | — | — |
EV/FCF |
(4.90) | (0.60) | (5.07) | (2.36) | (3.16) | 0.00 | — | — |
Quick Ratio |
15.85 | 6.76 | 7.35 | 6.64 | 11.99 | 4.70 | — | — |
Current Ratio |
16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 4.73 | — | — |
Net Debt/EBITDA |
3.08 | 1.75 | 2.93 | 3.35 | 8.48 | 3.70 | — | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Asset Turnover |
0.17 | 0.12 | 0.09 | 0.05 | 0.10 | 0.07 | 0.00 | — |
Operating CF/Net income |
1.37 | 1.01 | 1.16 | 1.01 | 1.02 | (1.35) | — | — |
Capex/Depreciation |
2.57 | 0.36 | 1.56 | (4.78) | (2.05) | (1.54) | — | — |
| (37.23%) | (57.58%) | (40.49%) | (36.41%) | (30.38%) | (20.50%) | — | — | |
| (28.41%) | (36.24%) | (24.25%) | (23.10%) | (16.46%) | (50.15%) | 0.00% | — | |
ROIC |
(2,661.91%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Return on Tangible Assets |
(29.97%) | (55.15%) | (32.77%) | (32.72%) | (12.76%) | (33.20%) | — | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 29.36 | 19.71 | 95.35 | — | — |
Research and Development Expense of Revenue |
211.86% | 342.10% | 315.38% | 426.01% | 209.59% | 652.96% | — | — |
Selling, General and Administrative Expense of Revenue |
66.54% | 103.99% | 97.19% | 120.78% | 47.50% | 128.85% | — | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
42.37% | 68.69% | 52.23% | 57.24% | 21.15% | 23.04% | — | — |
Graham Net Nets |
0.29 | 0.44 | 0.21 | 0.29 | 0.50 | (0.02) | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(9.71%) | (39.16%) | (11.02%) | (16.83%) | (8.58%) | 0.00% | — | — |
Free Cash Flow Yield |
(13.60%) | (39.19%) | (12.66%) | (18.19%) | (9.03%) | 0.00% | — | — |
Revenue per Share |
0.54 | 0.39 | 0.39 | 0.28 | 0.60 | 0.24 | — | — |
Operating CF per Share |
(1.20) | (1.20) | (1.25) | (1.24) | (0.96) | 2.19 | — | — |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.09) | (0.03) | (0.03) | — | — |
Free Cash Flow per Share |
(1.20) | (1.21) | (1.26) | (1.33) | (0.99) | 2.16 | — | — |
Cash per Share |
2.96 | 2.36 | 3.57 | 4.18 | 7.82 | 5.96 | — | — |
Shareholders Equity per Share |
2.98 | 1.83 | 2.68 | 2.84 | 5.55 | 1.21 | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
2.98 | 1.83 | 2.68 | 2.84 | 5.55 | 1.21 | — | — |
Free Cash Flow |
(139.93) | (132.25) | (119.51) | (116.77) | (61.36) | 68.97 | — | — |
Working Capital |
332.08 | 228.17 | 300.60 | 319.73 | 451.65 | 152.72 | — | — |
Capital Expenditures |
(1.05) | (0.75) | (1.53) | (7.69) | (1.84) | (1.11) | — | — |
Net Current Asset Value |
301.25 | 149.37 | 197.08 | 188.28 | 336.93 | 24.98 | — | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.02 | 0.02 | 0.04 | 0.31 | 0.05 | 0.14 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
(0.06) | (0.26) | (0.10) | 0.15 | 0.19 | 0.19 | — | — |
Cash ROIC |
(20.29%) | (28.91%) | (20.23%) | (18.95%) | (7.39%) | 30.13% | — | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 12.43 | 18.52 | 3.83 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
— | — | — | 2.00 | 2.00 | 2.00 | — | — |
Average Payables |
1.39 | 2.19 | 3.62 | 3.84 | 2.53 | 2.53 | — | — |
Average Assets |
357.59 | 359.53 | 419.52 | 468.31 | 353.70 | 103.63 | 0.00 | — |
Average Common Equity |
272.85 | 226.31 | 251.29 | 297.11 | 191.67 | 253.55 | — | — |
Columns are period end dates